AI could slash unnecessary prostate biopsies in 'Gray Zone' patients

NCT ID NCT07631806

Ongoing Diagnosis Sponsor: Guangxi Medical University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests an artificial intelligence system that combines blood tests, lab data, and ultrasound images to better diagnose prostate cancer in men with borderline PSA levels (4-10 ng/mL). The goal is to reduce unnecessary biopsies by accurately identifying who truly has cancer. The trial involves 500 men in China and uses biopsy results as the gold standard to measure the AI's accuracy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AI-assisted diagnostic system (combines ctDNA liquid biopsy, lab data, and ultrasound images)
What this could lead to: If successful, this could provide a more accurate, non-invasive way to diagnose prostate cancer in men with borderline PSA levels, reducing unnecessary biopsies.
What could go wrong: This is an early-stage validation study at a single hospital, so results may not apply to other populations. The AI system's accuracy depends on the quality of data and may still miss some cancers.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

disease prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER WITH PSA GRAY ZONE

Contacts and locations

Locations

Guangxi Medical University First Affiliated Hospital

Nan'ning, Guangxi, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.